Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘New’ DJO Will Focus On Realizing Cost-Savings And Synergies In 2008

This article was originally published in The Gray Sheet

Executive Summary

Rehabilitation and orthopedic device firm DJO, formerly ReAble Therapeutics, stressed cost savings and synergies March 24 in its first report of financial results following the completion of a major acquisition late last year

You may also be interested in...

ReAble Makes $1.6 Billion Move To Acquire Ortho Rehab Firm DJO

ReAble Therapeutics agreed July 16 to buy DJO for about $1.6 billion in a deal that will give the privately held firm a substantial stake in the bracing and soft goods orthopedic market and complement its current strength in electrotherapy pain management

Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts